Last updated: April 17, 2026
What Is HYRIMOZ?
HYRIMOZ (adalimumab-adaz) is a biosimilar to AbbVie's Humira (adalimumab). It is approved for autoimmune indications, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and others. Approved by the FDA in December 2019, HYRIMOZ launched in the U.S. market in 2020.
Market Position and Competition
HYRIMOZ entered a biosimilar market characterized by aggressive pricing and multiple competitors. Six biosimilars to Humira received FDA approval before or around 2019, with HYRIMOZ being one of the earliest to launch. The competition includes:
- Amgen's Amjevita (adalimumab-atto)
- Samsung Bioepis/Biogen's Imraldi (adalimumab-bwwd)
- Pfizer’s Abrilada (adalimumab-pbew)
- Celltrion’s Yuflyma (pending approval as of 2023)
Market Share and Adoption Trends
- As of 2023, biosimilars hold approximately 80% of new prescriptions for rheumatoid arthritis in the U.S.
- HYRIMOZ's market share remains below 10% of total Humira biosimilar prescriptions.
- U.S. biosimilar sales for adalimumab reached approximately $3.5 billion in 2022, with Humira accounting for most of this and biosimilars capturing an increasing share.
Pricing and Rebates
- Initial biosimilar launch price reductions ranged from 15% to 30% compared to Humira.
- Aggregate rebates for biosimilars are higher than those for the originator, often exceeding 30% of list prices.
- Contracting strategies favor bundling biosimilars with formulary privileges, affecting revenue distribution.
Market Drivers and Barriers
Drivers
- Patent expirations for Humira in the U.S. in 2023 opened access for biosimilar uptake.
- Cost savings from biosimilar substitution encourage payers and providers.
- Patient access programs and stepped therapy protocols favor biosimilar adoption.
Barriers
- Manufacturer rebates and formularies favoring the originator slow biosimilar penetration.
- Limited physician awareness and comfort with switching to biosimilars.
- Hospital procurement strategies and patient preference impact market share.
Financial Trajectory and Revenue Outlook
Revenue Projections
- Biosimilar adalimumab sales are expected to reach $7 billion globally by 2025 (Ref: IQVIA 2022).
- HYRIMOZ's U.S. revenue is projected to grow from approximately $100 million in 2022 to $250 million in 2025.
- The growth rate hinges on market penetration, pricing strategies, and payer acceptance.
Cost Structure
- Development costs: Biosimilar approval costs approximate $150 million, with manufacturing expenses around $1,000 per patient-year.
- Marketing expenses: To gain market share, companies spend significant sums on physician education and patient support, ranging from $30 million to $50 million annually per product.
Profitability
- Gross margins for biosimilars are marginally lower than originators due to discounts.
- Profitability improves with increased market share and cost efficiencies.
Regulatory and Policy Environment
- Patent litigation delays in some markets influence timing.
- U.S. biosimilar policy initiatives aim to incentivize substitution and value-based pricing.
- CMS and Medicare policies in 2023 favor biosimilar use through formulary and reimbursement arrangements.
Summary
HYRIMOZ operates in a competitive, price-sensitive biosimilar landscape. Market share remains limited due to entrenched brand loyalty and formulary dynamics. Revenue growth depends on expanding prescriber acceptance, payer negotiations, and eventual stabilization of biosimilar premiums. The landscape's evolution suggests augmenting uptake with aggressive pricing strategies and healthcare policy support.
Key Takeaways
- HYRIMOZ entered a mature biosimilar market with robust competition and price pressures.
- U.S. biosimilar adalimumab sales are rapidly growing, reaching an estimated $3.5 billion in 2022.
- Market share for HYRIMOZ remains under 10%, with growth driven by patent expiry and payer incentives.
- Revenue projections indicate potential to reach approximately $250 million in 2025 in the U.S.
- Policy and contractual arrangements heavily influence the pace of biosimilar adoption and revenue trajectory.
FAQs
1. How does HYRIMOZ compare price-wise to Humira?
HYRIMOZ launched with a list price approximately 15-30% lower than Humira, but actual net prices depend heavily on rebates and discounts negotiated with payers.
2. What is the expected timeline for HYRIMOZ to increase market share?
Market share growth hinges on payer policies, physician adoption, and competition. It is projected to increase gradually over the next 2–3 years, reaching around 20% of biosimilar prescriptions by 2025.
3. Are patent litigations affecting HYRIMOZ sales?
Patent litigation mainly affected Humira's exclusivity timeline, opening the market in 2023. HYRIMOZ itself has not faced significant legal hurdles delaying its market access.
4. Does government policy influence HYRIMOZ’s revenue?
Yes. Initiatives promoting biosimilar substitution and lower-cost alternatives help increase uptake, directly impacting HYRIMOZ’s sales volume.
5. What are the main challenges for HYRIMOZ's growth?
Entrenched prescriber preferences for the originator, rebate-driven formulary decisions, and aggressive competition from other biosimilars limit rapid growth.
References
[1] IQVIA. (2022). Biosimilar market report.
[2] FDA. (2019). FDA approves first interchangeable biosimilar for Humira.
[3] Deloitte. (2022). The biosimilar landscape: 2022 analysis.
